Financial Performance Expectations - The company expects a net profit loss for the year 2024, estimated between -74 million to -99 million CNY, compared to a profit of 10.47 million CNY in the same period last year[3] - The net profit after deducting non-recurring gains and losses is projected to be between -70 million to -94 million CNY, compared to a loss of 36.38 million CNY in the previous year[3] - Basic earnings per share are expected to be between -0.53 to -0.71 CNY, down from a profit of 0.07 CNY per share in the same period last year[3] Reasons for Decline in Profit - The decline in net profit is primarily due to reduced market demand and price adjustments, leading to decreased operating revenue[5] - Losses from affiliated enterprises have contributed to the decline in net profit attributable to shareholders[5] - Increased provisions for bad debts on accounts receivable have negatively impacted net profit[6] - The fair value of other non-current financial assets has decreased, further affecting net profit, classified as non-recurring losses[6] Financial Reporting and Investor Guidance - The financial data presented is preliminary and has not been audited by an external accounting firm[4] - The company will disclose detailed financial data in the 2024 annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks[7]
达安基因(002030) - 2024 Q4 - 年度业绩预告